 |
|
New Strategy for Inhibiting Virus Replication
August 17, 2009Cellular protein as a new target for treatment of chronic hepatitis C / Virologists from Heidelberg publish in PLoS Pathogens
Viruses need living cells for replication and production of virus progeny. Thus far, antiviral therapy primarily targets viral factors but often induces therapy resistance. New improved therapies attempt to targets cellular factors that are essential for viral replication.
The team led by Professor Dr. Ralf Bartenschlager, Director of the Department of Molecular Virology at the Hygiene Institute of Heidelberg University Hospital, has identified a protein in infected liver cells that is essential for hepatitis C virus replication. Inhibiting this protein is highly efficient in blocking virus replication. The study is to be published in the prestigious journal Public Library of Science Pathogens.
Viruses need cellular proteins for replication
More than 170 million people worldwide are affected by chronic hepatitis C. In up to 80 percent of infections, the virus can not be eliminated but persists in the infected individual. These chronically infected persons have a high risk of developing serious liver inflammation, liver cirrhosis and even a liver cell tumor.
Viruses contain only a minimum of genetic material and therefore need a host cell for replication. An essential cell factor required for hepatitis C virus replication is cyclophilin, which promotes the proper folding of proteins and the formation of large protein assemblies. Cyclophilin can be inhibited very efficiently by a drug used primarily in the context of organ transplantation - the immunosuppressant cyclosporin. In search for better tolerated drugs to trea chronic hepatitis C, derivatives of cyclosporin were developed that no longer suppress the immune system, but still effectively inhibit cyclophilin. One of these derivatives is DEBIO-025. Although the exact antiviral mechanism by which DEBIO-025 inhibits hepatitis C virus replication is not yet known, clinical studies are already being conducted.
The critical protein is cyclophilin A
A cell contains numerous variants of cyclophilins that are inhibited by cyclosporin and cyclosporin derivatives. The research team from Heidelberg analyzed liver cells to determine which cyclophilin is critical for hepatitis C virus replication. They found that only blocking cyclophilin A leads complete inhibition of virus replication and this cyclophilin is also the target of DEBIO-025.
Two complementary effects are responsible for the inhibition of hepatitis C virus replication: cyclophilin A is required both for the formation of the viral replication machinery and for the activity of a viral enzyme that is essential for the assembly of infectious virus particles. Inhibiting cyclophilin A with DEBIO-025 thus blocks hepatitis C virus replication from two different sides. By contrast, blocking cyclophilin B had no effect.
"The therapeutic potential of inhibiting cellular factors essential for virus replication has thus far hardly been tapped," explains Professor Bartenschlager. "But this approach has the major advantage that resistance arises less frequently and to a lesser extent in comparison to therapies directly targeting viral factors."
More Information on the Internet:
www.klinikum.uni-heidelberg.de/index.php?id=4722&L=en
Reference:
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. Artur Kaul, Sarah Stauffer, Carola Berger, Thomas Pertel, Jennifer Schmitt, Stephanie Kallis, Margarita Zayas Lopez, Volker Lohmann, Jeremy Luban, Ralf Bartenschlager. PLoS Pathogens, 2009.
University Hospital of Heidelberg
Viruses need cellular proteins for replication
More than 170 million people worldwide are affected by chronic hepatitis C. In up to 80 percent of infections, the virus can not be eliminated but persists in the infected individual. These chronically infected persons have a high risk of developing serious liver inflammation, liver cirrhosis and even a liver cell tumor.
Viruses contain only a minimum of genetic material and therefore need a host cell for replication. An essential cell factor required for hepatitis C virus replication is cyclophilin, which promotes the proper folding of proteins and the formation of large protein assemblies. Cyclophilin can be inhibited very efficiently by a drug used primarily in the context of organ transplantation - the immunosuppressant cyclosporin. In search for better tolerated drugs to trea chronic hepatitis C, derivatives of cyclosporin were developed that no longer suppress the immune system, but still effectively inhibit cyclophilin. One of these derivatives is DEBIO-025. Although the exact antiviral mechanism by which DEBIO-025 inhibits hepatitis C virus replication is not yet known, clinical studies are already being conducted.
The critical protein is cyclophilin A
A cell contains numerous variants of cyclophilins that are inhibited by cyclosporin and cyclosporin derivatives. The research team from Heidelberg analyzed liver cells to determine which cyclophilin is critical for hepatitis C virus replication. They found that only blocking cyclophilin A leads complete inhibition of virus replication and this cyclophilin is also the target of DEBIO-025.
Two complementary effects are responsible for the inhibition of hepatitis C virus replication: cyclophilin A is required both for the formation of the viral replication machinery and for the activity of a viral enzyme that is essential for the assembly of infectious virus particles. Inhibiting cyclophilin A with DEBIO-025 thus blocks hepatitis C virus replication from two different sides. By contrast, blocking cyclophilin B had no effect.
"The therapeutic potential of inhibiting cellular factors essential for virus replication has thus far hardly been tapped," explains Professor Bartenschlager. "But this approach has the major advantage that resistance arises less frequently and to a lesser extent in comparison to therapies directly targeting viral factors."
More Information on the Internet:
www.klinikum.uni-heidelberg.de/index.php?id=4722&L=en
Reference:
Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. Artur Kaul, Sarah Stauffer, Carola Berger, Thomas Pertel, Jennifer Schmitt, Stephanie Kallis, Margarita Zayas Lopez, Volker Lohmann, Jeremy Luban, Ralf Bartenschlager. PLoS Pathogens, 2009.
University Hospital of Heidelberg
Virus Replication Current Events and Virus Replication News RSSTriple-Combo Drug Shows Promise Against Antiviral-Resistant Swine Flu, UAB Researcher Says
An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases.
MicroRNAs grease the cell's circadian clockwork
Most of our cells possess an internal clock, a group of genes displaying a cyclic expression pattern that reaches a peak once a day.
USC researchers uncover mechanism that allows influenza virus to evade the body's immune response
Researchers at the University of Southern California (USC) have identified a critical molecular mechanism that allows the influenza virus to evade the body's immune response system.
Visualizing virus replication in 3 dimensions
Dengue fever is the most common infectious disease transmitted by mosquitoes - some 100 million people around the world are infected. Researchers at the Hygiene Institute at Heidelberg University Hospital were the first to present a three-dimensional model of the location in the human cell where the virus is reproduced.
Penn Study Identifies How Ebola Virus Avoids the Immune System
Researchers at the University of Pennsylvania School of Medicine have likely found one reason why the Ebola virus is such a powerful, deadly, and effective virus. Using a cell culture model for Ebola virus infection, they have discovered that the virus disables a cellular protein called tetherin that normally can block the spread of virus from cell to cell.
Study first to show that RNA interference can facilitate vaccine development
Pharmaceutical companies and universities are racing to develop drugs that use the gene silencing mechanism known as RNA interference to treat a host of diseases.
Well-armed immune cells help long-term nonprogressors contain HIV
To help develop an effective HIV vaccine, researchers are trying to better understand how the immune systems of a small minority of HIV-infected people known as long-term non-progressors (LTNPs) contain the virus naturally.
UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents.
Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS
Key differences in immune system signaling and the production of specific immune regulatory molecules may explain why some primates are able to live with an immunodeficiency virus infection without progressing to AIDS-like illness, unlike other primate species, including rhesus macaques and humans, that succumb to disease.
Discovery opens door for drugs to fight bird flu, other influenza epidemics
Researchers at Rutgers University and The University of Texas at Austin have reported a discovery that could help scientists develop drugs to fight the much-feared bird flu and other virulent strains of influenza.
More Virus Replication Current Events and Virus Replication News Articles
|
Plant Viruses Struc & Replication Vol 1 by C. L. Mandahar (Author) | |
 |
SciEd Virus Wall Charts; Virus Replication Chart by BioCam Virus Replication Chart |
|
Replication of Negative Strand Viruses: International Symposium Proceedings (Developments in cell biology) by D.H.L. Bishop (Editor), Richard W. Compans (Editor) | |
 |
Recent Advances in RNA Virus Replication 2006 by Kathleen Hefferon (Author), Kathleen L. Hefferon (Editor) This is the second part of a series on the molecular biology of virus application and has been compiled for those who would like to become acquainted with RNA virus replication as well as for specialists in the field. Special emphasis has been placed on research for scientists who are interested in further understanding the replication systems of DNA viruses with the purpose of developing viral expression vectors for gene therapy or for foreign expression of proteins. |
|
Virus Replication and Genome Interaction by The Company of Biologists Limited (Publisher) | |
|
VIRUS REPLICATION: An entry from Gale's World of Microbiology and Immunology by Gale (Publisher) This digital document is an article from World of Microbiology and Immunology, brought to you by Gale®, a part of Cengage Learning, a world leader in e-research and educational publishing for libraries, schools and businesses. The length of the article is 930 words. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Covers the concepts, theories, discoveries, and pioneers in microbiology and immunology, using a mix of traditional academic and topical articles, this title addresses current ethical, legal, and social issues with special emphasis given to biological warfare and terrorism. | |
 |
DNA Virus Replication (Frontiers in Molecular Biology) by Alan J. Cann (Editor) This book provides an overview of current research into DNA viruses. It is essential for all laboratories and students involved in DNA virus research. |
|
DNA Tumor Viruses: Control of Gene Expression and Replication (Cancer Cells, 4) by Michael Botchan (Author), Terri Grodzicker (Author), Phillip A. Sharp (Editor) | |
 |
Recent Advances in DNA Virus Replication 2006 by Kathleen L. Hefferon (Author), Kathleen L. Hefferon (Editor) This volume has been complied for those who are interested in familiarizing themselves with DNA virus replication in general, as well as for experts in the field who would find such a series of reviews assembled into a single book of great benefit for their own research programs. Molecular biologists and researchers in the field of medicine who are interested in further understanding the replication systems of DNA viruses with the purpose of developing viral expression vectors for gene therapy or for foreign expression of proteins will find this book of particular interest. |
|
The Biochemistry of Virus Replication Proceedings of the Fourth Meeting of the E by S.G. & Froholm, L.O., Editors; Nygaard, Symposi Laland (Author) |
| © 2009 BrightSurf.com |